Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Quarterly Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) announced its earnings results on Monday. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.06), Fidelity Earnings reports. Oramed Pharmaceuticals had a negative return on equity of 33.78% and a negative net margin of 822.72%.

Oramed Pharmaceuticals stock traded up $0.05 during midday trading on Wednesday, hitting $12.10. The company’s stock had a trading volume of 25,891 shares, compared to its average volume of 731,997. The company has a 50-day moving average price of $18.65 and a two-hundred day moving average price of $18.47. The company has a market cap of $460.84 million, a price-to-earnings ratio of -15.45 and a beta of 1.77. Oramed Pharmaceuticals has a 1-year low of $4.24 and a 1-year high of $31.54.

Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in Oramed Pharmaceuticals by 91.7% during the second quarter. Royal Bank of Canada now owns 3,834 shares of the biotechnology company’s stock worth $51,000 after buying an additional 1,834 shares during the last quarter. Wells Fargo & Company MN raised its stake in Oramed Pharmaceuticals by 57.2% in the second quarter. Wells Fargo & Company MN now owns 5,267 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 1,917 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Oramed Pharmaceuticals by 424.0% during the third quarter. BNP Paribas Arbitrage SA now owns 5,392 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 4,363 shares in the last quarter. Morgan Stanley increased its stake in shares of Oramed Pharmaceuticals by 63.8% in the first quarter. Morgan Stanley now owns 13,456 shares of the biotechnology company’s stock worth $137,000 after buying an additional 5,240 shares during the period. Finally, Invesco Ltd. bought a new stake in Oramed Pharmaceuticals in the second quarter valued at $154,000. Institutional investors and hedge funds own 15.49% of the company’s stock.

ORMP has been the subject of several analyst reports. Alliance Global Partners boosted their price objective on Oramed Pharmaceuticals from $25.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, November 9th. They noted that the move was a valuation call. HC Wainwright reissued a “buy” rating and set a $32.00 target price (up from $17.00) on shares of Oramed Pharmaceuticals in a research note on Monday, November 29th. Finally, Aegis boosted their price target on shares of Oramed Pharmaceuticals from $20.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, November 2nd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $34.25.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals, Inc engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.

Further Reading: Quiet Period Expirations

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.